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1. Introduction 
In studies [l-3] concerning the biochemical basis 
of the iqborn errors of metabolism, phenylketonuria 
(PKU), and maple syrup urine disease (MSUD), we 
have reported [3] that both phenylpyruvate and (Y- 
ketoisocaproate, which accumulate in tissues and 
plasma in PKU and MSUD respectively, markedly in- 
hibit the oxidation of pyruvate by rat brain mito- 
chondria. Furthermore, we suggested [3] that this 
may be due to an impairment of the access of pyruvate 
across the inner mitochondrial membrane to the py- 
ruvate dehydrogenase complex. Recently it has been 
reported [4] that a specific transport reaction exists 
for pyruvate across the rat liver mitochondrial mem- 
brane based on the discovery of a specific inhibitor 
for this process (a-cyano(4 hydroxy) cinnamate). We 
have therefore extended our studies on the effects of 
phenylpyruvate and cu-ketoisocaproate on pyruvate 
oxidation by rat brain mitochondria to include (11- 
cysnocinnamate and have also studied the effects of 
each of these inhibitors on /3-hydroxybutyrate oxida- 
tion by brain mitochondria. These latter experiments 
are particularly pertinent for PKU and MSUD since 
in the young brain, ketone bodies (mainly fl-hydroxy- 
butyrate) rather than pyruvate [5] are utilised as the 
main respiratory fuel, whereas in the adult brain pyru- 
vate is the main energy source [5]. 
The data indicate that not only pyruvate oxidation 
but also that of /3-hydroxybutyrate is markedly inhibi- 
ted by phenylpyruvate and cu-ketoisocaproate and even 
more so by a-cyanocinnamate. It is suggested that one 
of the primary lesions in both PKU and MSUD may 
be the impaired metabolism of pyruvate and fl-hy- 
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droxybutyrate by inhibition of the transport of these 
metabolites across the brain mitochondrial membrane. 
2. Materials and methods 
Brain mitochondria were prepared from male adult 
rats, (150- 160 g) for pyruvate studies or 22-day-old 
rats (SO-60 g) for /3-hydroxybutyrate studies, of the 
Wistar strain by the method of Clark and Nicklas [6]. 
Mitochondrial respiration was measured polarographi- 
tally at 28°C in an incubation medium consisting of 
(final concentrations) : 100 mM KC1 ,75 mM manni- 
tol, 25 mM sucrose, 10 mM phosphate-Tris, 10 mM 
Tris-HCl, 0.05 mM EDTA : final pH 7.4. To the 
medium, rat brain mitochondria were added ( - l-2 
mg protein/ml) followed by 2.5 mM malate and 5 mM 
pyruvate or 10 mM DL P-hydroxybutyrate (final con- 
centrations). State 3 [7] was induced by the addition 
of 250 PM ADP. The inhibitor under investigation was 
added during the state 4 [7] after one ADP cycle had 
been completed. Protein was measured by the method 
of Lowry et al. [8]. Phenylpyruvate and a-ketoiso- 
caproate were obtained from the Sigma Chemical Co., 
St. Louis, MO., USA and were used as 200 mM aqueous 
solutions. a-Cyanocinnamate was obtained from R. 
Emmanuel, Wembley, Middx., UK and was added as 
5 mM solution in ethanol: ethanol alone was added as 
control. 
3. Results 
Figs. 1 and 2 represent the effects of increasing 
concentrations of phenylpyruvate and a-ketoisoca- 
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proate on the oxidation of pyruvate and malate or 
/3-hydroxybutyrate and malate by rat brain mitochon- 
dria in state 3 ( t ADP) [7]. The results are expressed 
as a per cent of the control oxidation rate in the ab- 
sence of inhibitor. With both inhibitors pyruvate oxi- 
dation was inhibited to’s greater extent than p-hydroxy- 
butyrate oxidation - pyruvaie oxidation was in- 
hibited by 54% and 40% of the control by 2 mM 
phenylpyruvate or a-ketoisocaproate respectively, 
whereas fl-hydroxybutyrate oxidation was inhibited 
by only 36% and 30% under similar conditions. 
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Fig. 1. Effect of phenylpyruvate on the oxidation of pyru- 
vate (0) and P-hydroxybutyrate (A) by rat brain mitochon- 
dria. ‘fhe mitochondria were prepared by the method of 
Clark and Nicklas (6 ] and were incubated in a medium con- 
taining 100 mM K’ (see Materials and methods) together 
with 5 mM pyruvate and 2.5 mM malate or 10 mM DL p 
hydroxybutyrate and 2.5 mM malate. State 3 [ 71 was induced 
by the addition of 250 r.tM ADP and the inhibitor added 
during the ensuing state 4. The respiration rates (state 3 and 
4) in the presence of inhibitor was then estimated by the addit- 
ion of 2 or 3 aliquots of ADP. The results are the averages of 
at least 2 estimations of the state 3 rate expressed as a per 
cent of the average of the comparable state 3 rates in the 
absence of inhibitor. The control of respiration rates for 5 
mM pyruvate and 2.5 mM matate were state 3 = 183 f 13 
(SD - n=lS)natoms 0 min-’ mg protein-’ state 4 = 23 f 5 
(SD - n=15) natoms 0 min-’ mg protein-’ (adult rats); for 
10 mM DL P-hydroxybutyrate and 2.5 mM malate, state 3 = 
106 f 7 (SD - n=5) natoms 0 min.-’ mg. protein-‘, state 
4 = 26 * 4 (SD - ~15) natoms 0 min-’ mg protein-’ (22- 
day-old rats). 
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Fig. 2. Effect of a-ketoisocaproate on the oxidation of pyru- 
vate (0) and p hydroxybutyrate (A) by rat brain mitochondria. 
The experimental conditions were as in fig. 1 except that a- 
ketoisocaproate was used as the inhibitor. 
Furthermore, for both substrates phenylpyruvate 
appears to be more inhibitory than a-ketoisocaproate. 
Figs. 3 and 4 show similar experiments using o-cyano- 
cinnamate as an inhibitor. This compound inhibited 
bF---++ o-o 0.8 1.0 5-o 20.0 
pM- o( cyanocinnamate 
Fig. 3. Effect of a-cyanocinnamate on the oxidation of 
pyruvate by rat brain mitochondria. Experimental conditions 
were as in fg. 1 except that a-cyanocinnamate was used as the 
inhibitor. 
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Fig. 4. Effect of a-cyanocinnamate on oxidation of P_hydroxy- 
butyrate by rat brain mitochondria. Exptrimental conditions 
as in fig. 3. 
pyruvate oxidation by 75% at a final concentration 
of 20 w (fig. 3) whereas /3-hydroxybutyrate oxida- 
tion was inhibited by 70% at a final concentration of 
2 mM cu-cyanocinnamate (fig. 4). There were no inhi- 
bitory effects of phenylpyruvate, cr-ketoisocaproate 
or cY-cyanocinnamate on the state 4 (-ADP) respiration 
rate of brain mitochondria under similar conditions 
to those in fig. l-4. In addition no significant inhibi- 
tory effects have been observed on the state 3 oxida- 
tion rate of glutamate and malate or succinate by up to 
2 mM phenylpyruvate or a-ketoisocaproate. The 
oxygen uptakes, in natoms 0 min-' . mg protein-’ in 
state 3 were: for glutamate and malate (control), 159 
+ 3.5; for control + 2 mM phenylpyruvate, 139 f 4; 
for succinate oxidation were (control) 16.5 + 4; for 
control + 2 mM phenylpyruvate, I63 f 5; for control 
t 2 mM x-ketoisocaproate, 164 * 2. See also [4] for 
cr-cyanocinnamate. Studies with semi-purified prep- 
arations of pyruvate dehydrogenase and /3-hydroxybu- 
tyrate dehydrogenase indicate that phenylpyruvate, 
o-cyan0 (4-hydroxyj cinnamate have little or no 
inhibitory effects on the isolated enzyme system at 
the concentrations used in these experiments ([ 1,3,4] 
Clark and Land, unpublished observations). 
The absence of any effect of these compounds on 
the isolated enzymes (pyruvate dehydrogenase and 
/3-hydroxybutyrate dehydrogenase) and their marked 
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and specific effects on the oxidation of pyruvate and 
P-hydroxybutyrate, is consistent with the interpre- 
tation that phenylpyruvate, a-ketoisocaproate and 
cY-cyanocinnamate are inhibiting the transport of 
pyruvate and f3-hydroxybutyrate across the inner 
mitochondrial membrane, which in itself may be 
taken as evidence for the existence for both a pyruvate 
and fl-hydroxybutyrate carrier system. Such an inter- 
pretation is supported by the recent report of Halestrap 
and Denton [4] who have suggested (on the basis of a 
specific inhibition by cr-cyano(4 hydroxy) cinnamate) 
that in liver mitochondria and human erythrocytes a 
pynrvate carrier exists. What is of particular interest, 
however, especially in the brain, is the existence of a 
mitochondrial carrier for fl-hydroxybutyrate, which if 
not part of the same system as the pyruvate carrier, 
is clearly closely related to it since all three inhibitors 
affect both pyruvate and &hydroxybutyrate oxidation. 
Further evidence for the existence of both a pyruvate 
and /3-hydroxybutyrate carrier and their close interrela- 
tionship has been derived from experiments with heart 
and liver mitochondria which have been preloaded with 
[r4C] pyruvate or /3-hydroxybutyrate [9]. Studies have 
indicated that pyruvate will exchange for /3-hydroxybuty. 
rate and vice versa and that both phenylpyruvate and 
cu-ketoisocaproate will inhibit these exchanges. Similar 
exchange reactions between /3-hyfroxybutyrate and pyr- 
uvate in whole brain mitochondria have also been found 
to be inhibited by phenylpyruvate and a-ketoisocaproate 
(J. M. Land, J. B. Clark and T. Mowbray, unpublished 
observations). 
Although at the lower inhibitor concentrations fl- 
hydroxybutyrate oxidation appears more inhibited 
than pyruvate oxidation, the ultimate extent to which 
oxidation is inhibited appears always greater with 
pymvate as substrate (figs. l-4). A possible explana- 
tion of this is that at the higher inhibitor concentra- 
tions the decrease in intramitochondrial pyruvate con- 
tent [9] results additionally in an inactivation of the 
pyruvate decarboxylase unit of the pyruvate dehy- 
drogenase complex [IO] . Halestrap and Denton [4] 
suggested that pyruvate is transported as the enol form 
and in that case presumably it is the enol forms of 
phenylpyruvate and cr-ketoisocaproate which are the 
inhibitory species. Precise data concerning the enolisa- 
tion of phenylpyruvate and ol-ketoisocaproate are not 
available [ 1 ,l l] , although at the pH of the experi- 
ments the concentration of the enol forms of these 
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two a-keto acids would be several orders of magnitude 
less than that of the keto form. This may account for 
the apparent effectiveness of a-cyanocinnamate as an 
inhibitor of pyruvate oxidation (33% inhibition at 
0.75 - 1 mM). 
These inhibitions of both pyruvate and fl-hydroxy- 
butyrate oxi$ation in brain mitochondria by phenyl- 
pyruvate and a-ketoisocaproate may well have impor- 
tant consequences for the understanding of PKU and 
MSUD. In both these inborn errors of metabolism, if 
untreated, a defective brain myelination and mental 
retardation occurs [ 12,131 . Myelination occurs fairly 
early on during brain development [ 141 and during 
this period the brain of the young animal is mainly 
dependent on ketone bodies for its respiratory fuel 
[5] , pyruvate mainly being involved in an anaplerotic 
function [15] and Land and Clark, in preparation). 
Hence any inhibition of ketone body (fl-hydroxybuty- 
rate) utilisation in the brains of young animals by 
phenylpyruvate or a-ketoisocaproate would have dele- 
terious effects not only for the provision of carbon 
skeleton for fatty acid and cholesterol synthesis, for 
myelin deposition, but also for general energy provi- 
sion. Even when the brain has developed and utilises 
mainly glucose for its respiratory fuel [5] the presence 
of phenylpyruvate and cu-ketoisocaproate would still 
effectively prevent pyruvate utilisation. There have 
been a number of reports concerning the concentra- 
tions to which phenylpyruvate and a-ketoisocaproate 
rise in PKU and MSUD [l-3,12,1 31, the consensus 
of which seems to be that levels 0.5-l mM in the 
plasma and tissues are most likely. Thus from our data 
it may be seen that quite a marked inhibition of pyru- 
vate and fi-hydroxybutyrate oxidation will be achieved 
under these conditions. It may be proposed, therefore, 
that a primary lesion in phenylketonuria and maple 
syrup urine disease is the inhibition of pyruvate and 
/3-hydroxybutyrate utilisation by the inhibition of the 
transport of these substrates across the mitochondrial 
membrane. 
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